Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice.
Elaine S. Jaffe,Paul M. Barr,Sonali M. Smith +2 more
- Vol. 37, Iss: 37, pp 535-546
Reads0
Chats0
TLDR
This article will summarize the key changes in terms of diagnosis and histopathologic definitions, the impact of these changes on clinical management, and the challenges of future research in this field.Abstract:
Improved delineation of lymphoid malignancy biology has prompted refinement of the 2008 World Health Organization (WHO) classification of hematopoietic and lymphoid tumors with a new framework introduced in 2016 This knowledge has provided valuable insights regarding management Early clonal proliferations have been set apart given their limited potential for malignant dissemination Increasing knowledge of molecular drivers of aggressive lymphomas has allowed subclassification and opportunity for clinical investigations to personalize therapy New insights into T-cell pathophysiology has allowed grouping based on shared molecular and cellular features This article will summarize the key changes in terms of diagnosis and histopathologic definitions, the impact of these changes on clinical management, and the challenges of future research in this fieldread more
Citations
More filters
Journal ArticleDOI
Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia
Łukasz Sędek,Prisca M J Theunissen,Elaine Sobral da Costa,Alita J. van der Sluijs-Gelling,Ester Mejstrikova,Giuseppe Gaipa,Alicja Sonsala,Magdalena Twardoch,Elen Oliveira,Michaela Novakova,Chiara Buracchi,Jacques J.M. van Dongen,Alberto Orfao,Alberto Orfao,Vincent H.J. van der Velden,Tomasz Szczepański +15 more
TL;DR: It is shown that CD73, CD86 and CD304 are aberrantly (over)expressed in a substantial percentage of BCP-ALL patients and that their expression profile remains relatively stable early after starting therapy, supporting their potential contribution to improved MRD analysis by flow cytometry.
Journal ArticleDOI
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53
Manman Deng,Manman Deng,Mingzhi Zhang,Zijun Y. Xu-Monette,Lan V. Pham,Alexandar Tzankov,Carlo Visco,Xiaosheng Fang,Govind Bhagat,Feng Zhu,Karen Dybkær,April Chiu,Wayne Tam,Youli Zu,Eric D. Hsi,William W.L. Choi,Jooryung Huh,Maurilio Ponzoni,Andrés J M Ferreri,Michael Boe Møller,Benjamin M. Parsons,J. Han van Krieken,Miguel A. Piris,Jane N. Winter,Fredrick B. Hagemeister,Lapo Alinari,Yong Li,Michael Andreeff,Bing Xu,Ken H. Young,Ken H. Young +30 more
TL;DR: It is suggested that XPO1 worsens the survival of DLBCL patients with unfavorable prognostic factors such as BCL2 overexpression and double-hit, in line with the higher efficacy of selinexor demonstrated in B CL2 -R + DL BCL and HGBCL-DH cell lines.
Journal ArticleDOI
Oral and oropharyngeal diffuse large B-cell lymphoma and high-grade B-cell lymphoma: A clinicopathologic and prognostic study of 69 cases.
Carla Isabelly Rodrigues-Fernandes,Arnaldo Gonçalves Junior,Ciro Dantas Soares,Thayná Melo de Lima Morais,Gleyson Kleber do Amaral-Silva,Maria Goretti Freire de Carvalho,Lucas Lacerda de Souza,Fábio Ramôa Pires,Teresa Cristina Ribeiro Bartholomeu dos Santos,Débora Lima Pereira,Luis Rivero,Kelly Tambasco Bezerra,Bruno Augusto Benevenuto de Andrade,Mário José Romañach,Michele Agostini,Javier Rendón Henao,Amanda de Farias Gabriel,Décio dos Santos Pinto Júnior,Manoela Domingues Martins,Mateus José de Carvalho Pereira,Ricardo Alves Mesquita,Ricardo Santiago Gomez,Giovanna Ribeiro Souto,Alan Roger Santos-Silva,Pablo Agustin Vargas,Márcio Ajudarte Lopes,Oslei Paes de Almeida,Flávia Sirotheau Corrêa Pontes,Hélder Antônio Rebelo Pontes,Rommel Rodríguez Burbano,Felipe Paiva Fonseca +30 more
TL;DR: Patients affected by oral/oropharyngeal DLBCL have a low survival rate and female sex, presence of pain and ulcer, microscopic "starry sky pattern" and necrosis, co-expression of c-Myc/Bcl2, and translocation of MYC were associated with a lower survival in univariate analysis.
Journal ArticleDOI
Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma
TL;DR: In this paper , the relative prognostic roles of DLBCL genetic, phenotypic, and microenvironmental biomarkers were revealed, and they demonstrated independent and additive prognostic effects.
Journal ArticleDOI
Hodgkin lymphoma involving the tonsil misdiagnosed as tonsillar carcinoma: A case report and review of the literature.
TL;DR: This case serves as a reminder important role of biopsy as the reason of an extreme rare occurrence of HL involving the tonsil, doctors can easily misdiagnose the disease as tonsillar lymphoepithelial carcinoma.
References
More filters
Journal ArticleDOI
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Ash A. Alizadeh,Michael B. Eisen,R. Eric Davis,Izidore S. Lossos,Andreas Rosenwald,Jennifer C. Boldrick,Hajeer Sabet,Truc Tran,Xin Yu,John Powell,Liming Yang,Gerald E. Marti,Troy Moore,James I. Hudson,Li-Sheng Lu,David B. Lewis,Robert Tibshirani,Gavin Sherlock,Wing C. Chan,Timothy C. Greiner,Dennis D. Weisenburger,James O. Armitage,Roger A. Warnke,Ronald Levy,Wyndham H. Wilson,M. R. Grever,John C. Byrd,David Botstein,Patrick O. Brown,Louis M. Staudt +29 more
TL;DR: It is shown that there is diversity in gene expression among the tumours of DLBCL patients, apparently reflecting the variation in tumour proliferation rate, host response and differentiation state of the tumour.
Journal ArticleDOI
A revised European-American classification of lymphoid neoplasms : a proposal from the international lymphoma study group
Nancy L. Harris,Elaine S. Jaffe,Harald Stein,Peter M. Banks,John K.C. Chan,Michael L. Cleary,Georges Delsol,C. De Wolf Peeters,Brunangelo Falini,K C Gatter +9 more
Journal ArticleDOI
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow,Elias Campo,Stefano Pileri,Nancy L. Harris,Harald Stein,Reiner Siebert,Ranjana H. Advani,Michele Ghielmini,Gilles Salles,Andrew D. Zelenetz,Elaine S. Jaffe +10 more
TL;DR: The revision clarifies the diagnosis and management of lesions at the very early stages of lymphomagenesis, refines the diagnostic criteria for some entities, details the expanding genetic/molecular landscape of numerous lymphoid neoplasms and their clinical correlates, and refers to investigations leading to more targeted therapeutic strategies.
Journal ArticleDOI
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
Christine P. Hans,Dennis D. Weisenburger,Timothy C. Greiner,Randy D. Gascoyne,Jan Delabie,German Ott,H. Konrad Muller-Hermelink,Elias Campo,Rita M. Braziel,Elaine S. Jaffe,Zenggang Pan,Pedro Farinha,Lynette M. Smith,Brunangelo Falini,Alison H. Banham,Andreas Rosenwald,Louis M. Staudt,Joseph M. Connors,James O. Armitage,Wing C. Chan +19 more
TL;DR: In summary, immunostains can be used to determine the GCB and non-GCB subtypes of DLBCL and predict survival similar to the cDNA microarray.
Journal ArticleDOI
World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.
Nancy L. Harris,Elaine S. Jaffe,Jacques Diebold,G. Flandrin,H. Konrad Muller-Hermelink,James W. Vardiman,T. Andrew Lister,Clara D. Bloomfield +7 more
TL;DR: The experience of developing the WHO Classification has produced a new and exciting degree of cooperation and communication between oncologists and pathologists from around the world, which should facilitate progress in the understanding and treatment of hematologic malignancies.